🇺🇸 FDA
Patent

US 7714109

Combinations and kits for cancer treatment using selected antibodies to aminophospholipids

granted A61KA61K2039/505A61K39/395

Quick answer

US patent 7714109 (Combinations and kits for cancer treatment using selected antibodies to aminophospholipids) held by The Board of Regents of the University of Texas System expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue May 11 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
53
CPC classes
A61K, A61K2039/505, A61K39/395, A61K39/39558, A61K47/62